These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33595618)

  • 21. Natural history and extracutaneous involvement of congenital morphea: Multicenter retrospective cohort study and literature review.
    Mansour M; Liy Wong C; Zulian F; Li S; Morishita K; Yeh EA; Stewart K; Laxer RM; Pope E
    Pediatr Dermatol; 2018 Nov; 35(6):761-768. PubMed ID: 30187959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Morphea in Childhood: An Update.
    Aranegui B; Jiménez-Reyes J
    Actas Dermosifiliogr (Engl Ed); 2018 May; 109(4):312-322. PubMed ID: 29248149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinico-epidemiological Study of Morphea from a Tertiary Care Hospital.
    Arif T; Adil M; Amin SS; Tahseen M; Dorjay K; Mohtashim M; Singh M; Bansal R; Raj D
    Curr Rheumatol Rev; 2018; 14(3):251-254. PubMed ID: 29637865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality of Life in Patients with Morphea: A Cross-Sectional Study and a Review of the Current Literature.
    Szczęch J; Samotij D; Jaworecka K; Tobiasz A; Reich A
    Biomed Res Int; 2020; 2020():9186274. PubMed ID: 32258158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Classification and epidemiology of scleroderma.
    Mayes MD
    Semin Cutan Med Surg; 1998 Mar; 17(1):22-6. PubMed ID: 9512103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deep morphea.
    Bielsa I; Ariza A
    Semin Cutan Med Surg; 2007 Jun; 26(2):90-5. PubMed ID: 17544960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between quality of life and clinical characteristics in patients with morphea.
    Bali G; Kárpáti S; Sárdy M; Brodszky V; Hidvégi B; Rencz F
    Qual Life Res; 2018 Oct; 27(10):2525-2532. PubMed ID: 29922914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disease course and long-term outcome of juvenile localized scleroderma: Experience from a single pediatric rheumatology Centre and literature review.
    Martini G; Fadanelli G; Agazzi A; Vittadello F; Meneghel A; Zulian F
    Autoimmun Rev; 2018 Jul; 17(7):727-734. PubMed ID: 29729451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on the classification and treatment of localized scleroderma.
    Bielsa Marsol I
    Actas Dermosifiliogr; 2013 Oct; 104(8):654-66. PubMed ID: 23948159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma.
    Sato S; Fujimoto M; Ihn H; Kikuchi K; Takehara K
    J Am Acad Dermatol; 1994 Oct; 31(4):567-71. PubMed ID: 8089281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Major histocompatibility complex class I and class II alleles may confer susceptibility to or protection against morphea: findings from the Morphea in Adults and Children cohort.
    Jacobe H; Ahn C; Arnett FC; Reveille JD
    Arthritis Rheumatol; 2014 Nov; 66(11):3170-7. PubMed ID: 25223600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Morphea and Eosinophilic Fasciitis: An Update.
    Mertens JS; Seyger MMB; Thurlings RM; Radstake TRDJ; de Jong EMGJ
    Am J Clin Dermatol; 2017 Aug; 18(4):491-512. PubMed ID: 28303481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pansclerotic morphea with features of eosinophilic fasciitis: distinct entities or part of a continuum?
    Odhav A; Hoeltzel MF; Canty K
    Pediatr Dermatol; 2014; 31(2):e42-7. PubMed ID: 24383741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Localized scleroderma: clinical and epidemiological features with emphasis on adulthood- versus childhood-onset disease differences.
    Lis-Święty A; Skrzypek-Salamon A; Ranosz-Janicka I; Brzezińska-Wcisło L
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1595-1603. PubMed ID: 28271552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disabling pansclerotic morphea: clinical presentation in two adults.
    Maragh SH; Davis MD; Bruce AJ; Nelson AM
    J Am Acad Dermatol; 2005 Aug; 53(2 Suppl 1):S115-9. PubMed ID: 16021158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Localized Scleroderma Cutaneous Assessment Tool: responsiveness to change in a pediatric clinical population.
    Kelsey CE; Torok KS
    J Am Acad Dermatol; 2013 Aug; 69(2):214-20. PubMed ID: 23562760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pediatric morphea (localized scleroderma): review of 136 patients.
    Christen-Zaech S; Hakim MD; Afsar FS; Paller AS
    J Am Acad Dermatol; 2008 Sep; 59(3):385-96. PubMed ID: 18571769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case study: periodic follow-up is necessary in morphea profunda to identify systemic evolution.
    Melani L; Cardinali C; Giomi B; Schincaglia E; Caproni M; Fabbri P
    Skinmed; 2005; 4(3):188-90. PubMed ID: 15891259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Diagnostic and therapeutic problems of scleroderma].
    Pogorzelska-Antkowiak A; Antkowiak R
    Wiad Lek; 2006; 59(5-6):392-5. PubMed ID: 17017489
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.